Organization (Industry)
VERTEX PHARMACEUTICALS INC / MA
ClinicalTrials.gov lists VERTEX PHARMACEUTICALS INC / MA as lead sponsor of 12 trials, counting the companies grouped under it. VERTEX PHARMACEUTICALS INC / MA itself has 80 active development programs and 35 approved assets.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. Companies grouped under this one are not included. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 18 registered with a 2026 start date. The hollow diamonds on the dashed line are a forecast of the full-year count, planned starts included: about 20 in 2026 and about 18 in 2027, the average of the 24 months through October, counted as registered and carried forward. The columns, the lighter one included, count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. This method has not been backtested on organizations. In backtests on conditions with as many trial starts a year as this organization (5 to 20), forecasts made part-way through the year were typically off by about 28 percent and ran about 20 percent low against the count later registered; forecasts made before the year began were off by about 39 percent and ran about 37 percent low against the count later registered. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored. 2 trials are registered to start in 2027 or later.
Logo Vertex Pharmaceuticals Company, via Wikimedia Commons, Public domain. Shown to identify the organization; it may be a registered trademark.
This page covers VERTEX PHARMACEUTICALS INC / MA and 2 companies with a profile grouped under it (a further 2 registry-linked records in the group have no profile): 12 lead-sponsored trials (0 its own, 12 in the grouped companies) and 3 legal-entity registrations (1 its own, 2 in the grouped companies).
Companies grouped under this page (2)
Shown in this order: most lead trials first.
| Company | Country | Lead trials | Legal entities |
|---|---|---|---|
| Alpine Immune Sciences (United States) | US | 7 | 1 |
| ViaCyte (United States) | US | 5 | 1 |
Counts companies with a profile grouped under this one. A further 2 registry-linked records in this group have no company profile and are not listed.
Disease areas (53)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Cystic Fibrosis | 132 |
| Hepatitis C | 46 |
| Pain | 40 |
| Hepatitis C, Chronic | 21 |
| Acute Pain | 11 |
Showing 5 of 53 disease areas.
Trials by start year as sponsor or collaborator (24)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 2 trials are registered to start in 2027 or later, and not listed here.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2026 (partial year) | 18 |
| 2025 | 16 |
| 2024 | 22 |
| 2023 | 16 |
| 2022 | 25 |
| 2021 | 11 |
| 2020 | 10 |
| 2019 | 10 |
| 2018 | 16 |
| 2017 | 15 |
Showing 10 of 24 years.
Prediction, not a registry value: median 36 months or more (the model's horizon) from start to primary completion across 27 trials still running at the 2026-10-09 snapshot; 18 of 27 predicted trials reach the 36-month horizon; registered median of 12 months across 202 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Active development programs (80)
Shown in this order: max phase, then active trials.
| Drug | Disease area | Max phase | Trials | Ownership basis |
|---|---|---|---|---|
| CTX001 | Anemia | Phase 3 | 5 | Experimental arm |
| IVA | Cystic Fibrosis | Phase 3 | 47 | Experimental arm |
| ELX/TEZ/IVA | Cystic Fibrosis | Phase 3 | 24 | Experimental arm |
| CTX001 | Thalassemia | Phase 3 | 4 | Experimental arm |
| CTX001 | beta-Thalassemia | Phase 3 | 4 | Experimental arm |
Showing 5 of 80 active programs.
Approved assets (35)
Shown in this order: max phase first.
| Drug | Trials | Ownership basis |
|---|---|---|
| Suzetrigine | 24 | Regulatory holder |
| Telaprevir | 19 | Regulatory holder |
| Ribavirin | 19 | Generic, not holder |
| PEGinterferon alfa-2a | 15 | Crowded, not lead |
| LUM/IVA | 8 | Experimental arm |
Showing 5 of 35 approved assets.
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 73% hit target (n=115) | 65% on time (n=106) |
Journals published in (75)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| The New England journal of medicine | 21 |
| Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society | 19 |
| The Lancet. Respiratory medicine | 18 |
| American journal of respiratory and critical care medicine | 12 |
| Annals of the American Thoracic Society | 4 |
Showing 5 of 75 journals.
US granted patents (1)
Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.
| US patents granted | Granted in the last 5 years | Most recent grant |
|---|---|---|
| 1,317 | 146 | 2025-12-30 |
SEC-reported annual financials (11)
Shown in this order: newest fiscal year first; SEC EDGAR XBRL companyfacts; non-USD filers converted to USD at the annual average rate.
| Fiscal year | Revenue | Net income | R&D |
|---|---|---|---|
| 2025 | $12.0B | $3.95B | $3.91B |
| 2024 | $11.0B | -$536M | $3.63B |
| 2023 | $9.87B | $3.62B | $3.16B |
| 2022 | $8.93B | $3.32B | $2.54B |
| 2021 | $7.57B | $2.34B | $1.94B |
| 2020 | $6.21B | $2.71B | $1.64B |
| 2019 | $4.16B | $1.18B | $1.75B |
| 2018 | $3.05B | $2.10B | $1.42B |
| 2017 | $2.49B | $263M | $1.32B |
| 2016 | $1.70B | -$112M | $1.05B |
Showing 10 of 11 fiscal years.
Financing and grant events (4)
Shown in this order: most recent first; amounts in US dollars.
| Date | Round type | Amount | Source |
|---|---|---|---|
| 2025-02-13 | Follow-on offering | not disclosed | EDGAR offerings |
| 2022-02-09 | Other financing | not disclosed | EDGAR offerings |
| 2021-04-06 | Private placement | $53.9M | Form d |
| 2020-03-20 | Private placement | $32.6M | Form d |
Manufacturing and distribution sites (4)
Shown in this order: severity rank then name.
| Facility | Location | Regulators | Member organization |
|---|---|---|---|
| Vertex Pharmaceuticals (Canada) Incorporated | 20 Bay Street 1520, Toronto, CA | Health Canada | Vertex Pharmaceuticals (Canada) |
| Vertex Pharmaceuticals Incorporated | 50 Northern Avenue, Boston, US | FDA, Health Canada, USDA APHIS | |
| VERTEX PHARMACEUTICALS INCORPORATED | 1 HARBOR STREET, BOSTON, US | EMA, Health Canada | |
| Vertex Pharmaceutical Incorporated | 50 Northern Avenue, Boston, US | Health Canada |
Organization relationships (31)
Shown in this order: most evidence first.
| Related organization | Relationship | Evidence |
|---|---|---|
| Cystic Fibrosis Foundation | Co sponsors trial with | 14 |
| CRISPR Therapeutics AG | Co sponsors trial with | 5 |
| Children's Hospital of Philadelphia | Co sponsors trial with | 3 |
| Parion Sciences (United States) | Co sponsors trial with | 3 |
| Université de Montréal | Co sponsors trial with | 2 |
Showing 5 of 31 relationships.
Latest dated events (1,622)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2027-07-31 | Planned start | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2027-01-05 | Planned start | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-11 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-10-23 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-10-16 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
Showing 5 of 1,622 events.
Biomarker capability evidence (445)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| AFP | Trial collaborator | Named in trial inclusion criteria |
| AFP | Trial collaborator | Named in trial inclusion criteria |
| AFP | Trial collaborator | Named in trial inclusion criteria |
| ALB | Trial collaborator | Named in trial inclusion criteria |
| ALB | Trial collaborator | Named in trial inclusion criteria |
Showing 5 of 445 evidence rows.
Not on this page
Checked, with nothing recorded for this organization: related companies not grouped here, fda warning letters, fda untitled letters, fda inspection record, fda recalls, fda import refusals, climate targets, as filed, workforce and board diversity, as filed, clia clinical laboratory certificates, and biomarkers this organization publishes on.